Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANO: Somatostatin Analogs vs No Treatment in MEN1 NF-pNETs
NCT02705651Phase 3Unknown
- Sponsor
- Medical University of Vienna
- Start
- Dec 2019
- Primary completion
- Oct 2023
01
Overview
Phase 3, randomised, open-label trial in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Growth rate of the tumor at 5 years. Status: unknown.
02
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02705651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705651.